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Bipolar disorder is a debilitating mental illness characterized by recurrent episodes of 
mania and depression. FDA-approved drugs lithium and valproate, are the most common 
treatments for this disorder. Currently, omega-3 fatty acids are being researched as an 
alternative treatment, free of the negative side effects valproate and lithium exhibit. The 
mechanisms by which valproate and lithium work are unclear, however they effectively lower 
intracellular inositol levels. Valproate and omega-3 fatty acids similarly inhibit yeast cell 
growth as well as protein kinase C activity. We hypothesize that omega-3 fatty acids can also 
decrease inositol levels. A prodrug combining structural properties of valproate and omega-3 
fatty acids was synthesized and tested on the growth of Saccharomyces cerevisiae yeast cells. 
Results suggest the mechanisms by which valproate and omega-3 fatty acids lower inositol 
























Bipolar disorder is a chronic mental illness affecting approximately 1.3-1.5% of the 
American population (Azab et al., 2007; Azab and Miriam L. Greenberg, 2006). The disorder 
is characterized by mood swings ranging from lows of depression to highs of mania. Lithium 
and valproate are two of the most commonly used drugs for treating the symptoms of 
bipolar disorder. Although the mechanisms by which they remedy bipolar disorder are not 
clearly known, studies have shown both valproate and lithium target the inositol biosynthetic 
pathway, inhibiting steps of inositol synthesis, and effectively lowering inositol levels (Vaden 
et al., 2001). Inositol a is a chemical compound that forms the basis of many second 
messenger systems in cells of the human body. As a second messenger molecule, inositol 
relays signals from the surface of the cell to the targets within that cause changes in cell 
activity. Inositol is also an essential component of cell membranes.  
Lithium and valproate are not always effective in treating bipolar disorder, thus there 
is a need for more effective treatments. Currently omega-3 fatty acids are being researched as 
an alternative treatment for bipolar disorder. In combination with other treatments, omega-3 
fatty acids effectively reduce symptoms of this illness without the adverse side effects 
exhibited by lithium and valproate (Ross et al., 2007).  Interestingly valproate (Murray and 
Greenberg, 2000) and omega-3 fatty acids similarly inhibit growth in yeast cells (Murray, 
unpublished) and also the activity of protein kinase C (PKC) (Mirnikjoo et al., 2001), an 
enzyme involved in the inositol biosynthetic pathway. Therefore we hypothesize both 
compounds suppress inositol levels in yeast by similar mechanisms of action. My first goal in 
this research project is to synthesize a chloro linoleate acylal (α-chloropropyl linoleate) in a 
one-pot reaction involving linoleic acid, a model system for omega fatty acids. Finally, I 
would like to determine the effects of the prodrug on the inositol biosynthetic pathway by 




measuring the growth of wild type (SMY7) and mutant (SH1 and SH7) Saccaromyces cerevisiae 
yeast in the presence and absence of the synthesized compound. Saccaromyces cerevisiae yeast 
serves as a model system for the inositol biosynthetic pathway in the human body and its cell 
growth is dependent on inositol levels. SMY7 yeast produce normal levels of inositol 
whereas SH1 yeast under produce inositol and SH7 yeast over produce inositol. The prodrug 
has structural properties of both valproate and omega-3 fatty acids. Understanding how it 
affects the inositol biosynthetic pathway will shed light on the mechanisms by which both 
compounds work and contribute to evidence for the possible use of omega-3 fatty acids in 





A 50 ml round bottom flask and spin vane were dried in the oven overnight. The 
subsequent day the flask was placed in an ice bath over a magnetic stir plate, and capped 
with a calcium chloride drying tube. Cyclohexane, linoleic acid and thionyl chloride were 
added to the flask and the calcium chloride drying tube replaced with a water-cooled 
condenser. The mixture was refluxed 30 minutes to create linoleyl chloride. Reflux involves 
boiling the solution with minimal evaporation and continual cooling of the vapor which is 
returned to the flask as a liquid. The linoleyl chloride was allowed to cool to room 
temperature after which the condenser was replaced with the drying tube. Propanal and zinc 
oxide (catalyst) were added to the flask and stirred at room temperature for 90 minutes. The 
solution was extracted three times using fresh dichloromethane and deionized water each 




time. The solution was dried with anhydrous sodium sulfate for three days, rotovapped for 
20 minutes, and placed on a vacuum line for 24 hours to ensure the removal of solvent from 
the desired product. The density and actual yield of the product was determined. 1H and 13C 
nuclear magnetic resonance (NMR) and infrared (IR) spectroscopy were performed to 
analyze the product in relation to the starting materials, propanal and linoleic acid. Table 1 






A 100ml round bottom flask was dried in the oven overnight. The flask was placed 
on an ice bath over a magnetic plate and capped with a calcium chloride drying tube. 
Cyclohexane, linoleic acid, thionyl chloride and a spin vane were added to the flask.  The 
drying tube was replaced with a water condenser and the mixture refluxed for 45 minutes at 








Cyclohexane _ _ 10 0.779 84.16 
linoleic acid 0.0064 _ 2 0.9 280.45 
thionyl chloride 0.0084 _ 0.62 1.64 118.97 
Propanal 0.0064 _ 0.46 0.81 58.08 
zinc oxide 0.00128 0.104 _ 5.61 81.41 
dichloromethane _ _ 60 _ _ 




80˚C. The linoleyl chloride was allowed to cool to room temperature. The water condenser 
was again replaced by the drying tube. Propanal and zinc oxide (catalyst) were added to the 
flask and stirred at room temperature for 120 minutes. The mixture was extracted three 
times using fresh dichloromethane and deionized water, then dried with anhydrous sodium 
sulfate to remove excess water. After a few minutes of drying, the solution was rotovapped. 
In the midst of the rotary evaporation the flask containing the solution broke in the 
apparatus. The solution was collected as best as possible, reextracted, dried with anhydrous 
sodium sulfate and rotovapped for 10-20 minutes. 1H and 13C NMR of the product were 
performed. The product was placed on a vacuum line for futher purification and 1H and 13C 
NMR were performed again for analysis of the product in relation to the starting materials 













Cyclohexane _ _ 20 0.779 84.16 
linoleic acid 0.0128 _ 4 0.9 280.45 
thionyl chloride 0.0168 _ 1.24 1.64 118.97 
Propanal 0.0128 _ 0.92 0.81 58.08 
zinc oxide 0.0026 0.208  5.61 81.41 
dichloromethane _ _ 40 _ _ 






Liquid media for the yeast was prepared using the ingredients listed in Table 3. Two 
types of media were made: one with inositol (I+) and one without inositol (I-). The 
ingredients for 500 mL of media were mixed into two 1 L Erlenmeyer flasks, labeled either 
I+ or I- . Media in the I+ labeled flask included myo-inositol whereas the flask labeled I- did 
not. These flasks were covered with aluminum foil and autoclaved for 25 minutes along with 
three empty 250 mL Erlenmeyer flasks, two labeled I- and one labeled I+. Then, 100 mL 
each of the I+ and I- media was poured into its corresponding 250 mL flask. The I+ flasks 
was then inoculated with plated SH1 yeast and labeled as such. One of the I- flasks  was 
inoculated with plated SMY7 yeast and the other with plated SH7 yeast and labeled 
respectively. The inoculations were allowed to grow for 24-30 hours in a shaker bath (150 
rpm; 30 °C). After this, 1000 µl of stock I+ media was pipetted into a cuvette as a control, 
900 µl of stock I+ media was placed in a second cuvette as well as 100 µl from the I+. 1000 
µl of stock I- media was pipetted into a cuvette as a control, and for each I- flask 900 µl of 
stock I+ media was placed in a cuvette as well as 100 µl from the overnight flask. 
Concentration readings were then taken with the spectrophotometer to confirm that there 
was enough growth to continue on with next step (at least 0.1).  
After autoclaving six new empty 250 mL Erlenmeyer flasks, each flask was labeled 
wildtype, underproducer, overproducer, wildtype + PD, underproducer + PD, and 
overproducer + PD (PD corresponds to prodrug). 100 mL of I+ media was added to the 
underproducer and underproducer + PD flasks and 100 mL of I- media was added to each 
of the other four flasks. Based on calculations using the formula C1V1 = C2V2, specific 
volumes of the I+ and I- overnight solutions were added to the corresponding flasks 




containing new media. The prodrug flasks contained both the overnight solution and a 
prodrug concentration of 5.0 mM. These six flasks were placed in a shaker bath (150 rpm; 30 
°C) for 24-30 hours. Another concentration reading was taken of the resulting cells using the 
spectrophotometer. A 10-3 dilution was then performed on the resulting solutions For each 
solution 10 µl of the solution and 990 µl of water were placed in a 1 mL microcentrofuge 
tube. Each was spread on a previously made YPD plate and labeled (see Table 3). The plates 
were incubated for 48 hours and then the resulting yeast colonies were counted. 
 
Trial 2 
The same steps for preparing the yeast and allotting the prodrug in Trial 1 were repeated. A  
10-3 dilution was performed on the resulting solutions and plated on YPD plates. The plates 




Vitamin Free Yeast Base 0.345 mL 
Ammonium sulfate 1.005 mL 
Glucose 10 g 
100x vitamins 10 g 
Myo-inositol* 5 mL 
Adenine 7.5 mL 
Arginine 1 mL 
Histidine 1 mL 
Leucine 2 mL 
Lysine 1 mL 
Methionine 1 mL 
Threonine 8 mL 
Tryptophan 1 mL 
Uracil  8 mL 
Deionized H2O 500 mL 
Agar** 10g 
*Only used for I+ media for SH1/underproducer yeast 
**Only used to make YPD plates 





NMR and IR ANALYIS: 
Trial 1 yielded a product with a density of .966g/ml and actual yield of 1.9ml. Table 4 
summarizes the important spectral features in the IR, 1H NMR, and 13C NMR spectroscopy 
for propanal, linoleic acid and the product, α-chloropropyl linoleate. The important spectral 
features for Trial 1 and Trial 2 were the same. 
 
Table 4 
 Important Spectral Features 
Compound IR (cm-1) 1H NMR (ppm) 13C NMR (ppm) 
 
Propanal 










 C=O (1761) 
 C-O  (1136)  
acylal H, triplet @ 6.4 
present 
aldehyde H @ 9.8 
is gone 
Present: 
acylal carbon @ 85 
ester carbon @ 172 
Absent: 
aldehyde carbon @ 204 


























































Prodrug No prodrug 







The IR of the prodrug showed two main diagnostic peaks that indicate the success 
of the reaction. There was a peak at 1761 cm-1 and at 1136 cm-1, which are characteristic of 
C=O and C-O groups respectively. The 1H NMR propanal 9.8 ppm that was absent for the 
prodrug. Also the characteristic acylal proton showed up as a triplet peak at 6.4ppm for the 
prodrug. The 13C NMR confirmed the success of the reaction. Most of the carbon atoms in 
the propanal and linoleic acid stayed in relatively the same positions throughout the reaction. 
The peak for the aldehyde carbon  in propanal (204ppm) as well as the peak for the acid 
carbon in linoleic acid (180 ppm) were absent in the13C NMR of the prodrug. Instead a peak 
for the acylal carbon at 85 ppm and for the ester carbon at 172 ppm were present for the 
prodrug, indicating we had obtained the desired product. 
  
BIOLOGICAL TESTING: 
We hypothesized that the prodrug would effectively lower the inositol levels of the 
yeast causing a decrease in cell growth.  In Trial 1 wildtype (SMY7) yeast treated with the 
prodrug had no growth. The yeast underproducing inositol (SM1) had a less drastic decrease 
in growth. Yeast overproducing inositol did not grow with or without the drug, so there may 
have been a mistake made in plating the cells. In Trial 2 the wildtype yeast treated with 
prodrug had low cell counts (14) in comparison to the control (175). Both the 
underproduing and overproducing yeast treated with prodrug had no growth. 
 
 





Based on the NMR and IR analysis, the prodrug synthesis was successful for both 
trials, inspite of the accident that could have resulted in contamination for Trial 2.  Overall 
the prodrug is effective at inhibiting growth however the inhibition of growth was the same 
in all three strains. This suggests the effect of the prodrug is not related to the inositol 
biosynthetic pathway. However a comparison of cell counts for each yeast cell type in Trial 1 
and Trial 2 does not demonstrate similar numbers. Further testing needs to be done for 
results from the biological testing to be concrete. Future experiments should include more 
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